Currently out of the existing stock ratings of Jason Zemansky, 25 are a BUY (58.14%), 15 are a HOLD (34.88%), 3 are a SELL (6.98%).

Jason Zemansky

Work Performance Price Targets & Ratings Chart

Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 50.62% that have a potential upside of 14.38% achieved within 75 days.

Jason Zemansky’s has documented 84 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RCUS, Arcus Biosciences at 28-Nov-2025.

Wall Street Analyst Jason Zemansky

Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for INSM (INSMED) at 10/27/2025. The price target of $187 was fulfilled within 3 days with a profit of $22.98 (14.01%) receiving and performance score of 46.7.

Average potential price target upside

of $24.3 (37.77%) on ALVR (ALLOVIR ).
of $14.87 (36.36%) on INSM (INSMED).
of $7.51 (17.87%) on CYTK (CYTOKINETICS).

ALLK Allakos CYTK Cytokinetics ESPR Esperion Therapeutics INSM Insmed HOWL Werewolf Therapeutics RCUS Arcus Biosciences ALVR Allovir KURA Kura Oncology SNDX Syndax Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Wolleben (JMP)